IMD-0354 optimization generates potent colistin adjuvants with in vivo activity and reduced eukaryotic toxicity
Luke J Cowart, Ansley M Nemeth, Leigh A Jania, Moira Overly, Courtney F Ellis, Beverly H Koller, Roberta J Melander, Yohei Doi, Robert K Ernst, Christian Melander · 2026
Read IMD-0354 optimization generates potent colistin adjuvants with in vivo activity and reduced eukaryotic toxicity by Luke J Cowart, Ansley M Nemeth, Leigh A Jania, Moira Overly, Courtney F Ellis, Beverly H Koller, Roberta J Melander, Yohei Doi, Robert K Ernst, Christian Melander (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13479383.txt.
Description
Luke Cowart and nine colleagues optimized in 2026 IMD-0354 derivatives into colistin adjuvants with lower toxicity. Colistin is a last-resort drug against heavily drug-resistant Gram-negative bacteria, but resistance to it is rising and the parent scaffold harms human cells.
New analogues kept colistin-helping power while cutting human-cell toxicity, with leads cutting the drug dose needed against highly resistant Acinetobacter baumannii and Klebsiella pneumoniae by up to 2,048-fold. Lead compound NDM-622 showed a safety margin of at least 50 and, with colistin, lowered bacterial counts in a mouse peritonitis model versus the drug alone. Early tests suggest these analogues act in a new way from IMD-0354 itself.
Catalog record
| CREATOR | Luke J Cowart, Ansley M Nemeth, Leigh A Jania, Moira Overly, Courtney F Ellis, Beverly H Koller, Roberta J Melander, Yohei Doi, Robert K Ernst, Christian Melander |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |